Related Experiment Video

Updated: Apr 14, 2026

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

8.0K

Influence of microRNA-related polymorphisms on clinical outcomes in coronary artery disease

Qianzhen Li1, Liangwan Chen1, Daozhong Chen1

  • 1Department of Cardiovascular Surgery, Union Hospital, Fujian Medical University Fujian 350001, China.

American Journal of Translational Research
|April 23, 2015
PubMed

Insights

Genetic variants in microRNAs (miRNAs) impact coronary artery disease (CAD) prognosis. Specific polymorphisms, miR-4513 rs2168518 and miR-499 rs3746444, are linked to patient survival and mortality risk.

Area of Science:

  • Genetics
  • Cardiovascular Disease
  • Molecular Biology

Background:

  • Genetic variations in microRNA (miRNA) genes and their targets can affect gene expression and disease outcomes.
  • MicroRNAs play a crucial role in regulating cellular processes and are implicated in various human diseases.

Purpose of the Study:

  • To investigate the association between six miRNA-related polymorphisms and the clinical prognosis of coronary artery disease (CAD).
  • To identify potential miRNA biomarkers for predicting CAD outcomes.

Main Methods:

  • Genotyping of six miRNA polymorphisms (miR-149 rs71428439, miR-146a rs2910164, miR-499 rs3746444, miR-423 rs6505162, miR-4513 rs2168518, and FABP2 rs11724758) in 1004 angiographic CAD patients.
  • Statistical analysis to correlate genotypes with clinical parameters and patient survival.

Main Results:

  • miR-4513 rs2168518 was associated with blood pressure, lipid profiles, glucose levels, and diabetes risk.
  • miR-499 rs3746444 and miR-423 rs6505162 showed associations with blood pressure and HDL levels, respectively.
  • Both miR-4513 rs2168518 and miR-499 rs3746444 significantly impacted event-free survival, with miR-4513 rs2168518 linked to increased mortality in CAD patients.

Conclusions:

  • miR-4513 rs2168518 and miR-499 rs3746444 may serve as valuable biomarkers for predicting the clinical prognosis of coronary artery disease.
  • These genetic variants could influence disease progression and patient outcomes in CAD.
Keywords:
Coronary artery diseasecardiovascular eventlipidmicroRNAmortalitypolymorphism

More Related Videos

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization08:22

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization

Published on: September 15, 2018

8.7K
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.8K

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
127
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.3K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.8K
MicroRNAs01:22

MicroRNAs

12.1K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
70
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
94